Anaphylactic shock due to brentuximab-vendotin confirmed by skin test and in vitro tests

J Allergy Clin Immunol Pract. 2017 Sep-Oct;5(5):1427-1429. doi: 10.1016/j.jaip.2017.05.003. Epub 2017 Jun 19.

Authors

Blanca Noguerado-Mellado¹, Patricia Rojas-Pérez-Ezquerra², Mercedes Sáenz de Santa María García², Gabriela Rodriguez-Macías³, Pilar Tornero², Borja Bartolomé⁴

Affiliations

¹ Allergy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain. Electronic address: blancanoguerado@gmail.com.
² Allergy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain.
³ Gregorio Marañón Health Research Institute, Madrid, Spain; Haematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
⁴ Roxall, R&D Department, Bilbao, Spain.

PMID: 28634100
DOI: 10.1016/j.jaip.2017.05.003

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Anaphylaxis / chemically induced*
Anaphylaxis / diagnosis
Anaphylaxis / drug therapy
Anaphylaxis / immunology
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / immunology
Brentuximab Vedotin
Drug Hypersensitivity / diagnosis
Drug Hypersensitivity / drug therapy
Drug Hypersensitivity / etiology*
Drug Hypersensitivity / immunology
Female
Glucocorticoids / administration & dosage
Hodgkin Disease / diagnosis
Hodgkin Disease / drug therapy*
Humans
Immunoconjugates / adverse effects*
Immunoconjugates / immunology
Immunoglobulin E / immunology*
Methylprednisolone / administration & dosage
Predictive Value of Tests
Skin Tests*
Treatment Outcome

Substances

Glucocorticoids
Immunoconjugates
Immunoglobulin E
Brentuximab Vedotin
Methylprednisolone